Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry
Authors: Ian R Gough, Ian Dickinson, Guy Maddern, Michael Grigg and David J Hillis
Published online: 1 March 2010
To the Editor: Mitchell raises issues that strongly reflect on the professional standing of the medical profession.1 His particular focus is on the pharmaceutical industry, and on much needed changes as highlighted by Medicines Australia.2 Similar concerns exist in the medical technology industry where the transparency of relationships is becoming increasingly important.
Mitchell highlights the fact that self-regulation by the medical profession has been largely ineffective.1 In this day of international corporate activity in the delivery of health care, the declaration of the Hippocratic Oath is no longer sufficient. The Royal Australasian College of Surgeons (RACS) published a code of conduct in 2006.3 This has been supplemented recently by the code of conduct of the Australian Medical Council.4 Separately, the Medical Technology Association of Australia has published its guidelines for industry groups.5 However, the dominant criticism of these documents is that compliance is voluntary.
The RACS believes it is critical that the profession takes leadership in this complex issue to ensure that trust is maintained in the patient–doctor relationship. Consequently, we have recently expanded our code of conduct with a comprehensive policy dealing with interactions with the medical technology and pharmaceutical industries.6 We are introducing a sanctions policy to strengthen compliance. If there is a breach of the guidelines, the fellow or trainee concerned will need to confirm ongoing adherence to the RACS code of conduct. If there is a repeat offence, then cause will need to be given as to why the fellow should not have his or her fellowship removed or the trainee should not be dismissed from the training program.
As professionals, these issues of integrity, transparency and trust are fundamental. The doctor–patient relationship must be our primary focus, and should not be violated by any perceived or real conflict of interest.
Competing interests
References
- Mitchell PB. Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry. Med J Aust 2009; 191: 273-275. 0_CBBCHHGE
- Medicines Australia. Code of conduct. Edition 16. 2007. http://www.medicinesaustralia.com.au/pages/page5.asp (accessed Jan 2010).
- Royal Australasian College of Surgeons. Code of conduct. Melbourne: RACS, 2006. 0_i1091871
- Australian Medical Council. Good medical practice: a code of conduct for doctors in Australia. Canberra: AMC, 2009. 0_i1091873
- MTAA and MTANZ code of practice. 4th ed. Sydney: Medical Technology Association of Australia, 2008. 0_i1091875
- Royal Australasian College of Surgeons. Surgeons and trainees interactions with the medical industry. Guidelines and position paper. Melbourne: RACS, 2009. http://www.surgeons.org/Content/NavigationMenu/CollegeResources/Publications/Positionpapers/default.htm (accessed Jan 2010).